Core Viewpoint - Revvity, Inc. reported strong financial results for Q4 and full year 2025, exceeding expectations and positioning itself well for future growth in improving market conditions [6]. Financial Performance Summary Fourth Quarter 2025 - GAAP earnings per share (EPS) increased to $0.87 from $0.78 year-over-year [2]. - Revenue rose to $772 million, up from $729 million in the same period last year, marking a growth of approximately 5.9% [2]. - GAAP operating income from continuing operations was $112 million, down from $119 million, with an operating profit margin of 14.5%, compared to 16.3% a year ago [2]. - Adjusted EPS from continuing operations was $1.70, up from $1.42, while adjusted operating income increased to $229 million from $221 million [3]. Full Year 2025 - GAAP EPS for the year was $2.07, a decrease from $2.20 in 2024 [4]. - Total revenue for 2025 reached $2,856 million, compared to $2,755 million in 2024, reflecting a growth of approximately 3.7% [4]. - GAAP operating income from continuing operations was $357 million, slightly up from $347 million, with a profit margin of 12.5%, down from 12.6% [4]. - Adjusted EPS from continuing operations was $5.06, an increase from $4.90 in 2024, while adjusted operating income was $773 million, down from $779 million [5]. Segment Performance Life Sciences - Q4 2025 revenue was $382 million, a 2% increase from $375 million year-over-year [8]. - Full year revenue for Life Sciences was $1,431 million, up 2% from $1,399 million in 2024 [8]. - Adjusted operating income for Q4 was $136 million, down from $138 million, with a profit margin of 35.6%, compared to 36.9% a year ago [8]. Diagnostics - Q4 2025 revenue was $390 million, a 10% increase from $355 million year-over-year [8]. - Full year revenue for Diagnostics was $1,425 million, up 5% from $1,356 million in 2024 [8]. - Adjusted operating income for Q4 was $91 million, unchanged from the previous year, with a profit margin of 23.4%, down from 25.7% [8][9]. Guidance for 2026 - The company forecasts total revenue for 2026 to be between $2.96 billion and $2.99 billion, with organic revenue growth of 2-3% and adjusted EPS of $5.35 to $5.45 [10].

At Revvity, "impossible†is inspiration, and "can't be done†is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. WALTHAM, Mass.--(BUSINESS WIRE) ...